CY1125068T1 - Ενωσεις τετραϋποκατεστημενου αλκενιου και χρηση αυτων - Google Patents

Ενωσεις τετραϋποκατεστημενου αλκενιου και χρηση αυτων

Info

Publication number
CY1125068T1
CY1125068T1 CY20211100961T CY211100961T CY1125068T1 CY 1125068 T1 CY1125068 T1 CY 1125068T1 CY 20211100961 T CY20211100961 T CY 20211100961T CY 211100961 T CY211100961 T CY 211100961T CY 1125068 T1 CY1125068 T1 CY 1125068T1
Authority
CY
Cyprus
Prior art keywords
compounds
quatern
breast cancer
alkene compounds
subject
Prior art date
Application number
CY20211100961T
Other languages
English (en)
Inventor
Mark Bock
Ming-Hong Hao
Manav KORPAL
Vijay Kumar Nyavanandi
Xiaoling Puyang
Susanta Samajdar
Peter Gerard Smith
John Wang
Guo Zhu Zheng
Ping Zhu
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of CY1125068T1 publication Critical patent/CY1125068T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/02Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/02Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2
    • C07D317/06Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2 condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Στο παρόν έγγραφο γνωστοποιούνται ενώσεις ή φαρμακευτικώς αποδεκτά άλατα αυτών και μέθοδοι χρήσης των ενώσεων για τη θεραπευτική αντιμετώπιση του καρκίνου του μαστού με τη χορήγηση σε ένα υποκείμενο που χρήζει αυτής, μιας θεραπευτικώς δραστικής ποσότητας των ενώσεων ή των φαρμακευτικώς αποδεκτών αλάτων αυτών. Ο καρκίνος του μαστού δύναται να είναι καρκίνος του μαστού θετικός σε ER και/ή το υποκείμενο που χρήζει θεραπευτικής αντιμετώπισης δύναται να εκφράζει μια μεταλλακτή πρωτεΐνη ER-α.
CY20211100961T 2015-05-29 2021-11-08 Ενωσεις τετραϋποκατεστημενου αλκενιου και χρηση αυτων CY1125068T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562168581P 2015-05-29 2015-05-29
US201562168529P 2015-05-29 2015-05-29
US201562269745P 2015-12-18 2015-12-18
PCT/US2016/034782 WO2016196346A1 (en) 2015-05-29 2016-05-27 Tetrasubstituted alkene compounds and their use

Publications (1)

Publication Number Publication Date
CY1125068T1 true CY1125068T1 (el) 2023-03-24

Family

ID=57398096

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100961T CY1125068T1 (el) 2015-05-29 2021-11-08 Ενωσεις τετραϋποκατεστημενου αλκενιου και χρηση αυτων

Country Status (33)

Country Link
US (2) US9796683B2 (el)
EP (2) EP3981766A1 (el)
JP (1) JP6325760B1 (el)
KR (1) KR102664618B1 (el)
CN (2) CN107847498B (el)
AU (1) AU2016271126B2 (el)
BR (1) BR112017025546B1 (el)
CA (1) CA2987321C (el)
CL (1) CL2017002996A1 (el)
CO (1) CO2017013432A2 (el)
CY (1) CY1125068T1 (el)
DK (1) DK3302471T3 (el)
ES (1) ES2895511T3 (el)
HR (1) HRP20211542T1 (el)
HU (1) HUE056199T2 (el)
IL (1) IL255765B2 (el)
JO (1) JO3735B1 (el)
LT (1) LT3302471T (el)
MA (1) MA43364B1 (el)
MD (1) MD3302471T2 (el)
MX (1) MX2017015226A (el)
MY (1) MY186977A (el)
PE (1) PE20181083A1 (el)
PH (1) PH12017502142A1 (el)
PL (1) PL3302471T3 (el)
PT (1) PT3302471T (el)
RS (1) RS62481B1 (el)
RU (1) RU2733741C2 (el)
SI (1) SI3302471T1 (el)
TW (1) TWI704137B (el)
UA (1) UA120882C2 (el)
WO (2) WO2016196337A1 (el)
ZA (1) ZA201707912B (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI704137B (zh) 2015-05-29 2020-09-11 日商衛材R&D企管股份有限公司 四取代烯化合物及其等之用途
JP2019535778A (ja) * 2016-11-24 2019-12-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 四置換アルケン化合物及び乳がんを治療するためのその使用
MA46896A (fr) * 2016-11-24 2019-10-02 Eisai R&D Man Co Ltd Composés d'alcène tétrasubstitués et leur utilisation
EP3544967B1 (en) * 2016-11-28 2023-06-28 Eisai R&D Management Co., Ltd. Salts of indazole derivative and crystals thereof
KR102517650B1 (ko) * 2017-03-16 2023-04-05 에자이 알앤드디 매니지먼트 가부시키가이샤 유방암의 치료를 위한 조합물 요법
WO2019225552A1 (en) * 2018-05-22 2019-11-28 Eisai R&D Management Co., Ltd. Salts of indazole derivative and crystals thereof
KR20210105384A (ko) * 2018-12-17 2021-08-26 치아타이 티안큉 파마수티컬 그룹 주식회사 에스트로겐 수용체 길항제
AU2020274113A1 (en) 2019-05-14 2021-11-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
KR20220012891A (ko) 2019-05-24 2022-02-04 에자이 알앤드디 매니지먼트 가부시키가이샤 에스트로겐 수용체-알파 억제제의 경구 투여 형태로 암을 치료하는 방법
MX2021015486A (es) 2019-06-19 2022-01-24 Jiangsu Hengrui Medicine Co Derivado de indazol, metodo de preparacion y aplicacion farmaceutica del mismo.
CN110452177A (zh) * 2019-09-02 2019-11-15 南通大学 一种5-溴-4-氟-1h-吲唑的合成方法
WO2021097046A1 (en) 2019-11-13 2021-05-20 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2022001971A1 (zh) 2020-06-28 2022-01-06 南京明德新药研发有限公司 并环吲唑类化合物
WO2022098953A1 (en) 2020-11-06 2022-05-12 Eisai R&D Management Co., Ltd. Method of treating breast cancer
CN114644616B (zh) * 2020-12-18 2023-11-14 江苏恒瑞医药股份有限公司 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法
CN114644615B (zh) * 2020-12-18 2023-11-14 江苏恒瑞医药股份有限公司 一种吲唑类衍生物的结晶形式及其制备方法
TW202241879A (zh) * 2020-12-18 2022-11-01 大陸商江蘇恒瑞醫藥股份有限公司 一種吲唑類衍生物的藥學上可接受鹽、結晶形式及其製備方法
CA3214408A1 (en) 2021-03-23 2022-09-29 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2023272410A1 (zh) * 2021-06-27 2023-01-05 北京盛诺基医药科技股份有限公司 一种ERα受体共价结合拮抗剂

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3907290A1 (de) 1989-03-07 1990-09-13 Gerhard Prof Dr Eisenbrand Steroidhormonrezeptoraffine antitumorwirkstoffe
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
WO2007058626A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
WO2009120999A2 (en) 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
US8063249B1 (en) * 2008-04-25 2011-11-22 Olema Pharmaceuticals, Inc. Substituted triphenyl butenes
US8785501B2 (en) 2009-10-13 2014-07-22 Duquesne University Of The Holy Spirit Anti-cancer tamoxifen-melatonin hybrid ligand
WO2011129837A1 (en) 2010-04-16 2011-10-20 Olema Pharmaceuticals, Inc. Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
WO2013056178A2 (en) 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
NZ630124A (en) 2012-03-20 2016-01-29 Seragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
MX2015017655A (es) 2013-06-19 2016-04-15 Seragon Pharmaceuticals Inc Modulador de receptores de estrogeno y uso del mismo.
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
EP3116497A2 (en) 2014-03-13 2017-01-18 F. Hoffmann-La Roche AG Therapeutic combinations with estrogen receptor modulators
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
JP6807841B2 (ja) 2014-12-18 2021-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーター及びその使用
TWI704137B (zh) 2015-05-29 2020-09-11 日商衛材R&D企管股份有限公司 四取代烯化合物及其等之用途

Also Published As

Publication number Publication date
US10851065B2 (en) 2020-12-01
IL255765B1 (en) 2023-06-01
MA43364B1 (fr) 2021-11-30
HUE056199T2 (hu) 2022-01-28
KR20180011274A (ko) 2018-01-31
CL2017002996A1 (es) 2018-03-23
JP6325760B1 (ja) 2018-05-16
PH12017502142A1 (en) 2018-06-11
RU2017146408A3 (el) 2019-10-18
TW201706250A (zh) 2017-02-16
PT3302471T (pt) 2021-11-02
JO3735B1 (ar) 2021-01-31
ES2895511T3 (es) 2022-02-21
IL255765A (en) 2018-01-31
CA2987321A1 (en) 2016-12-08
SI3302471T1 (sl) 2021-11-30
US9796683B2 (en) 2017-10-24
EP3981766A1 (en) 2022-04-13
EP3302471A4 (en) 2018-10-10
EP3302471A1 (en) 2018-04-11
ZA201707912B (en) 2019-05-29
WO2016196346A1 (en) 2016-12-08
MD3302471T2 (ro) 2021-12-31
WO2016196337A1 (en) 2016-12-08
IL255765B2 (en) 2023-10-01
UA120882C2 (uk) 2020-02-25
CN107847498B (zh) 2021-04-13
MA43364A (fr) 2021-04-14
JP2018516250A (ja) 2018-06-21
HRP20211542T1 (hr) 2022-01-07
RU2017146408A (ru) 2019-07-02
DK3302471T3 (da) 2021-11-15
BR112017025546A2 (pt) 2018-08-07
CN113024466A (zh) 2021-06-25
LT3302471T (lt) 2021-10-11
AU2016271126B2 (en) 2020-09-24
CO2017013432A2 (es) 2018-05-21
TWI704137B (zh) 2020-09-11
PL3302471T3 (pl) 2022-02-07
US20160347717A1 (en) 2016-12-01
BR112017025546B1 (pt) 2023-02-14
MY186977A (en) 2021-08-26
RS62481B1 (sr) 2021-11-30
KR102664618B1 (ko) 2024-05-10
EP3302471B1 (en) 2021-08-25
MX2017015226A (es) 2018-02-19
AU2016271126A1 (en) 2017-12-07
RU2733741C2 (ru) 2020-10-06
CA2987321C (en) 2023-09-19
PE20181083A1 (es) 2018-07-05
US20180127378A1 (en) 2018-05-10
CN107847498A (zh) 2018-03-27

Similar Documents

Publication Publication Date Title
CY1125068T1 (el) Ενωσεις τετραϋποκατεστημενου αλκενιου και χρηση αυτων
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1125144T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης
CY1120421T1 (el) Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων
CY1124810T1 (el) Συνδυαστικη θεραπεια για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1123177T1 (el) Ρυθμιστης υποδοχεα ανδρογονου και χρησεις αυτου σε συνδυασμο με οξεικη αμπιρατερονη και πρεδνιζονη για τη θεραπεια καρκινου του προστατη
CY1122144T1 (el) Αιθερες αρυλιου και χρησεις εξ αυτων
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
EA201700464A1 (ru) Производные майтанзиноида, их конъюгаты и способы использования
CY1119510T1 (el) Συνδυασμος dr5 αγωνιστη και anti-pd1 ανταγωνιστη και μεθοδοι χρησης
GT201700025A (es) Inhibidores de la proteína quinasa c y métodos de su uso
CY1124078T1 (el) Συνθεσεις που περιλαμβανουν αναστολεα λυσινης ειδικης απομεθυλασης-1 που εχει δακτυλιο πυριμιδινης και χρηση αυτων στη θεραπεια καρκινου
CY1121849T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου
CY1119199T1 (el) Αναστολεις cdc7
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
CY1117712T1 (el) Adcs δουοκαρμυκινης για χρηση στη θεραπεια ενδομητριου καρκινου
CY1123216T1 (el) Αναστολεις της gls1 για την αντιμετωπιση νοσων
CY1123963T1 (el) Καινοτομα πολυμερικα προφαρμακα hgh
EA201692100A8 (ru) Новые антитела против rnf43 и способы их применения
CY1123614T1 (el) Μεθοδος θεραπειας δυσκινησιας
CL2017000050A1 (es) Terapia de combinación para el cáncer
CY1123019T1 (el) Σπειροκυκλικες ενωσεις
CY1121667T1 (el) Παραγοντες για θεραπεια τριπλα αρνητικου καρκινου μαστου
CY1120573T1 (el) Παραγωγα πυριδαζινης για χρηση στην προληψη ή θεραπεια αταξικης διαταραχης